<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Radiation-induced lung injury
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Radiation-induced lung injury
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Radiation-induced lung injury
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tobias Peikert, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dawn Owen, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James R Jett, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven E Schild, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation-induced lung injury (RILI) was first described in 1898, soon after the development of roentgenograms [
         <a href="#rid1">
          1
         </a>
         ]. The distinction between two separate types of RILI, radiation pneumonitis and radiation fibrosis, was made in 1925 [
         <a href="#rid2">
          2
         </a>
         ]. Both types of lung injury are observed today in patients who have undergone thoracic irradiation for the treatment of lung, esophageal, breast, or hematologic malignancies. Radiation-induced damage to normal lung parenchyma remains a dose-limiting factor in chest radiotherapy and can involve other structures within the thorax in addition to the lungs  (
         <a class="graphic graphic_table graphicRef79716" href="/z/d/graphic/79716.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         A large body of literature describes the histopathologic, biochemical, kinetic, physiologic, and molecular responses of lung cells to ionizing radiation [
         <a href="#rid3">
          3-7
         </a>
         ]. However, the clinical diagnosis of RILI is often complicated by the presence of other conditions, including malignancy, infection, drug induced lung injury/pneumonitis, and cardiogenic pulmonary edema [
         <a href="#rid8">
          8
         </a>
         ]. RILI will be reviewed here. The cardiac, esophageal, chest wall, and brachial plexus effects of therapeutic radiation to the chest are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7062.html" rel="external">
          "Cardiotoxicity of radiation therapy for breast cancer and other malignancies"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7054.html" rel="external">
          "Overview of gastrointestinal toxicity of radiation therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/754.html" rel="external">
          "Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4617.html" rel="external">
          "Stereotactic body radiation therapy for lung tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3747053982">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of radiation pneumonitis varies depending upon the radiation regimen used and upon the radiation field, both of which are influenced by the underlying neoplasm type and distribution. In addition, there is frequently a discrepancy between evidence of radiation changes on imaging and clinically relevant symptoms. The severity of radiation pneumonitis is graded based on impact on patient function and quality of life, not radiographic changes  (
         <a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">
          table 2
         </a>
         ). Estimated incidence of symptomatic (grade 2 or higher) RILI is described below for common tumor types:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients undergoing radiation therapy for lung cancer (conventional fractionation 1.8 to 2.0 Gy per day), symptomatic RILI developed in 7 percent of those who received more than 20 Gy (V
         <sub>
          20
         </sub>
         ) over 22 to 31 percent of the lung volume [
         <a href="#rid9">
          9
         </a>
         ]. The incidence of symptomatic RILI increased to 13 percent in those with a V
         <sub>
          20
         </sub>
         of 32 to 40 percent. In addition, in a separate study of 251 patients receiving stereotactic body radiotherapy (median dose: 60 Gy delivered in three fractions to the 80 percent isodose line), symptomatic RILI occurred in 9 percent overall but varied based on the radiation dose and volume of lung irradiated [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with breast cancer, symptomatic RILI occurs in approximately 1 to 9 percent depending on the extent of the radiation field and whether concurrent chemotherapy is administered [
         <a href="#rid11">
          11
         </a>
         ]. One to 3 percent of patients may also develop a less typical secondary organizing pneumonia [
         <a href="#rid12">
          12-15
         </a>
         ]. (See
         <a class="local">
          'Typical disease course'
         </a>
         below and
         <a class="local">
          'Chest computed tomography'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 110 patients with Hodgkin and non-Hodgkin lymphoma treated with intensity-modulated radiation therapy (IMRT), 14 percent developed symptomatic RILI. Of these, 5 percent were grade 3 (cough and dyspnea at rest) and none were grade 4 or 5  (
         <a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ionizing radiation causes the localized release of sufficient energy to break strong chemical bonds and generate highly reactive free radical species. Cellular molecules including peptides, lipids, and DNA (deoxyribonucleic acid) can be affected directly or more often indirectly via the interaction of the ionizing radiation with tissue water producing free radicals. These free radicals damage DNA strands as the primary method for radiation to kill cells.
        </p>
        <p>
         RILI results from the combination of direct cytotoxicity upon normal lung tissue and, perhaps more importantly, the development of fibrosis triggered by radiation-induced cellular signal transduction. Epithelial cell cytotoxicity largely proceeds directly as a consequence of DNA damage, which results in loss of cell division capability (clonogenic death) and apoptosis. The accompanying development of inflammation and fibrosis is mediated by cytokine activity and patient immune responses.
        </p>
        <p>
         Several proinflammatory cytokines are elevated in serum and tissues after radiation therapy, including transforming growth factor-beta 1 (TGF-beta), tumor necrosis factor-alpha (TNFa), interleukin- (IL-) 1a, and IL-6 [
         <a href="#rid17">
          17-21
         </a>
         ]. Some studies have found [
         <a href="#rid17">
          17,18,22-31
         </a>
         ] elevated pretreatment plasma IL-6 and posttreatment TGF-beta concentrations correlate with an increased risk of developing RILI [
         <a href="#rid17">
          17-20,32
         </a>
         ]. The role of immune regulation is supported by the observation that disruption of CD40/CD40 ligand interactions between antigen-presenting cells and CD40 ligand-bearing cells (T lymphocytes, mast cells, and eosinophils) reduces pathologic markers of injury in a murine model of RILI [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         These inflammatory responses to injury are likely mitigated by other signals of inflammation regulation and injury repair. For example, exogenous interferon-gamma administration reduced alveolar inflammation (neutrophil and protein levels) and pathologic features of radiation injury in a rat model of RILI [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many factors affect the development of radiation-induced lung disease. The volume of lung irradiated and the mean lung dose (MLD) are important risk factors, but do not completely explain differences in the risk of RILI across various tumors, radiation methods, and treatment schedules. Although data from studies based upon various radiation therapy parameters or gene polymorphisms have been studied as predictors of RILI [
         <a href="#rid36">
          36-38
         </a>
         ], these predictors are not yet clinically useful. We weigh the factors below in determining the risk of RILI after radiation therapy.
        </p>
        <p class="headingAnchor" id="H1262185703">
         <span class="h2">
          Volume of lung irradiated
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of radiation-induced injury is directly related to the volume of irradiated lung [
         <a href="#rid39">
          39,40
         </a>
         ]. In patients with breast cancer, for example, the risk of transient lung inflammation following adjuvant chest wall irradiation is approximately 5 percent. The risk is higher with increasing lung volume in the tangential fields, treatment to the regional lymph nodes (supraclavicular, axillary apex, and internal mammary regions [
         <a href="#rid41">
          41
         </a>
         ]), and the use of concurrent compared with sequential chemotherapy (8.8 versus 1.3 percent in one series) [
         <a href="#rid42">
          42
         </a>
         ]. In one report, when tangential beam irradiation was utilized following breast-conserving surgery, pneumonitis was observed only when &gt;10 percent of the lung was irradiated [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/789.html" rel="external">
          "Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1801346885">
         <span class="h2">
          Dose of radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of radiation delivered to the lung is a critical factor in determining if injury will occur [
         <a href="#rid39">
          39,44-48
         </a>
         ]. As noted above, MLD can be a predictor of the risk of radiation pneumonitis, as can the V
         <sub>
          20
         </sub>
         , defined as the volume of normal lung (total lung volume minus planning target volume for radiotherapy) that receives 20 Gy or greater [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         In 2010, a group of physicians and physicists analyzed more than 70 articles as part of the QUANTEC series to determine the radiation dose and lung volumes that predict a greater risk of pneumonitis with conventionally fractionated (daily doses of 1.8 to 2.0 Gy/day) radiotherapy [
         <a href="#rid39">
          39
         </a>
         ]. They concluded that MLD and V
         <sub>
          20
         </sub>
         were the best supported for routine clinical practice and recommended keeping the V
         <sub>
          20
         </sub>
         to ≤30 to 35 percent and MLD ≤20 to 23 Gy to keep the risk of pneumonitis ≤20 percent.
        </p>
        <p class="headingAnchor" id="H3057191419">
         <span class="h2">
          Time-dose factor
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a systematic review, the use of twice daily fractionation appeared to reduce the risk of RILI compared with administration of the same total daily dose as a single fraction [
         <a href="#rid49">
          49
         </a>
         ]. However, in a subsequent study of 37 patients receiving radiation for non-small cell lung cancer (NSCLC), 14 developed radiation pneumonitis, suggesting no benefit to the twice daily fractionation regimen [
         <a href="#rid50">
          50
         </a>
         ]. Due to lack of clear benefit and the increase in logistical difficulties, twice daily dose fractionation is rarely used for NSCLC. By contrast, twice daily fractionation is frequently used for limited-stage small cell lung cancer (SCLC). (See
         <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">
          "Limited-stage small cell lung cancer: Initial management", section on 'Dose fractionation schedule'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Method of irradiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation oncologists continue to work to improve the targeting of radiation, increasing the dose given to diseased tissue while sparing normal tissue [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment"
         </a>
         .)
        </p>
        <p>
         This general approach of shaping the distribution of therapeutic radiation dose within the patient to match as well as possible to the intended target volume, while minimizing the dose to other tissues, is often referred to as conformal radiation therapy (CRT). More specialized techniques of CRT include intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT). (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Stereotactic radiation therapy techniques'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Intensity-modulated radiation therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intensity-modulated radiation therapy
         </strong>
         – Although its impact on RILI has not been fully characterized, IMRT is increasingly recognized as a preferred option in locally advanced NSCLC. Observational data support the idea that the technical alterations in lung dosing with this technique reduce the likelihood of RILI. (See
         <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">
          "Management of stage III non-small cell lung cancer", section on 'Administration of radiation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a secondary analysis of the NRG Oncology clinical trial (RTOG 0617) that included 482 patients with locally advanced NSCLC, IMRT was administered to 227 patients and three-dimensional (3D) CRT to 255 [
         <a href="#rid52">
          52
         </a>
         ]. Two-year overall survival, progression-free survival, local failure, and distant metastasis-free survival were not different between the groups, but the rate of grade 3 pneumonitis was less with IMRT (7.9 versus 3.5 percent, p = 0.039).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study of chemoradiation for NSCLC, rates of pneumonitis from two sequential time periods were compared [
         <a href="#rid53">
          53
         </a>
         ]. In the earlier period, patients received 3D-CRT, while in the later period, 4D (four-dimensional; includes lung movement with respiration) IMRT was used. Chemotherapeutic approach did not change. Patients in the later period had a significantly lower volume of lung receiving more than 20 Gy (V
         <sub>
          20
         </sub>
         ) and a lower MLD and were less likely to develop pneumonitis than patients treated earlier.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stereotactic body radiation therapy
         </strong>
         – Clinically significant radiation pneumonitis develops in fewer patients (5 to 15 percent) treated with SBRT compared with conventional radiation therapy [
         <a href="#rid54">
          54-57
         </a>
         ]. This is likely attributable to lower irradiated lung volumes and a lower MLD. The risk of RILI increases once the V
         <sub>
          20
         </sub>
         exceeds 10 percent or the MLD is higher than 6 Gy [
         <a href="#rid58">
          58
         </a>
         ]. Thus, the increased accuracy of newer radiation models appears to reduce global measures of lung irradiation and radiation pneumonitis as well. Most recently, the HyTEC analyses were published and suggested that ipsilateral MLD be limited to &lt;15 Gy to maintain a risk of &lt;20 percent for grade 2 and above radiation pneumonitis [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proton beam therapy
         </strong>
         – The use of protons rather than photons may decrease the incidence of radiation pneumonitis by decreasing the volume of lung receiving a clinically significant dose. In a systematic review of proton beam therapy for breast cancer, only 1 of 102 patients across four studies developed radiation pneumonitis [
         <a href="#rid60">
          60
         </a>
         ]. Similarly, In a phase 2 study of high-dose proton therapy in combination with weekly
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         for unresectable NSCLC, 1 of 44 treated patients developed pneumonitis, suggesting that high-dose proton therapy administered concurrently with chemotherapy is well tolerated [
         <a href="#rid61">
          61
         </a>
         ]. Initial data from an observational study of 16 patients suggest that proton beam therapy may be safer than other radiation approaches in high-risk patients with fibrotic interstitial lung diseases (ILDs) who are undergoing radiation therapy for lung cancer [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prospective Phase II randomized data on the role of passive scatter proton therapy and intensity modulated radiation in definitive chemoradiation for lung cancer showed improved sparing of lung doses, although there was a learning curve with proton radiotherapy in lung cancer [
         <a href="#rid63">
          63
         </a>
         ]. There is an ongoing larger randomized trial of proton therapy versus IMRT as a component of stage II-IIIB NSCLC treatment (RTOG 1308).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More modern proton techniques (intensity-modulated proton therapy [IMPT]) may offer advances in organ sparing and may markedly reduce the rates of pneumonitis compared with photon IMRT [
         <a href="#rid64">
          64
         </a>
         ]. In one retrospective comparison, one study found that IMPT was associated with a highly reduced rate of grade ≥3 pneumonitis at one year compared with IMRT with photons (0 versus 11 percent) [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Proton beam'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H899567639">
         <span class="h2">
          Induction chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of induction chemotherapy prior to chemoradiotherapy may increase the risk of radiation pneumonitis [
         <a href="#rid65">
          65-67
         </a>
         ]. In a retrospective review of 96 patients treated for esophageal cancer, the incidence of moderate to severe pneumonitis at one year was higher among those who received induction chemotherapy prior to chemoradiotherapy compared with those who did not (49 versus 14 percent) [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Concurrent chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several chemotherapeutic agents are known sensitizers to radiotherapy, including
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , taxanes,
         <a class="drug drug_general" data-topicid="9318" href="/z/d/drug information/9318.html" rel="external">
          dactinomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , recombinant interferon-alpha, and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid11">
          11,65,68-71
         </a>
         ]. Patients receiving these drugs are at a higher risk of developing RILI. In addition, several of the drugs themselves are associated with lung injury  (
         <a class="graphic graphic_table graphicRef117782" href="/z/d/graphic/117782.html" rel="external">
          table 3
         </a>
         ). By contrast, other drugs may sensitize tumor cells to the effects of radiation without an increase in lung injury [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4349.html" rel="external">
          "Cyclophosphamide pulmonary toxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4355.html" rel="external">
          "Taxane-induced pulmonary toxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4327.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents"
         </a>
         .)
        </p>
        <p>
         A 2012 meta-analysis of eight studies and 1607 patients demonstrated an increased risk of radiation pneumonitis (odds ratio [OR] 1.6, 95% CI 1.1-2.3) in patients receiving concurrent compared with sequential chemotherapy. Other risk factors identified included older age, pulmonary comorbidities and mid- or lower-lung tumor location [
         <a href="#rid73">
          73
         </a>
         ]. Risks associated with particular agents are discussed further below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anthracyclines
         </strong>
         – Concurrent rather than sequential chemotherapy appears to increase the risk of radiation pneumonitis in females undergoing anthracycline-based adjuvant chemotherapy plus radiotherapy for breast cancer [
         <a href="#rid42">
          42,65
         </a>
         ]. In one report, the risk of pneumonitis in females treated with a supraclavicular field and concurrent versus sequential chemotherapy was 9 versus 1.3 percent, respectively [
         <a href="#rid42">
          42
         </a>
         ]. Because of this risk, concurrent anthracycline-based chemotherapy and radiation are generally avoided in the treatment of breast cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         – It is likely that sequential administration of paclitaxel and radiation therapy diminishes the risk of radiation pneumonitis as compared with concurrent treatment. However, females who receive taxanes as a component of their adjuvant therapy for breast cancer may also need to have a smaller volume of lung included in the radiation field. This topic is addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4355.html" rel="external">
          "Taxane-induced pulmonary toxicity", section on 'Concomitant radiotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/788.html" rel="external">
          "Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Timing of chemotherapy and radiation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          Gemcitabine
         </a>
         – Gemcitabine is included in many lung cancer treatment protocols and is a potent radiation sensitizer. When given as concurrent therapy at standard doses, pulmonary toxicity is prohibitive [
         <a href="#rid74">
          74
         </a>
         ]. Toxicity is prominent, even with reduced doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a series of 19 patients with NSCLC, induction chemotherapy with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (800 mg/m
         <sup>
          2
         </sup>
         ) followed by weekly gemcitabine (200 mg/m
         <sup>
          2
         </sup>
         ) concurrent with radiation was associated with grade 3 to 5 (fatal) radiation pneumonitis in 32 percent [
         <a href="#rid75">
          75
         </a>
         ]. However, radiation treatment planning in this report used a two-dimensional technique and the fields were large (including the primary lesion, grossly involved nodal sites, plus ipsilateral hilum, and mediastinum with a margin of 2 cm). Details about the dose to normal lung were not described. (See
         <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">
          "Management of stage III non-small cell lung cancer", section on 'Preferred approach: Chemoradiotherapy, followed by durvalumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients receiving concurrent
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , toxicity appears less with conformal (3D) compared with two-dimensional treatment planning [
         <a href="#rid76">
          76
         </a>
         ]. Toxicity is greater with regimens that include induction chemotherapy prior to chemoradiotherapy, combinations of gemcitabine with a taxane as opposed to a platinum-type drug, and more frequent dosing of gemcitabine (eg, 30 mg/m
         <sup>
          2
         </sup>
         twice weekly) [
         <a href="#rid66">
          66,76-78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          Pemetrexed
         </a>
         – The exact interaction of pemetrexed with irradiation is not known, although it appears to have some radiosensitizing and radiation recall effects [
         <a href="#rid79">
          79-81
         </a>
         ]. In the PROCLAIM trial of 598 patients with unresectable nonsquamous NSCLC, thoracic radiation therapy was administered concurrently with either pemetrexed plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         plus cisplatin [
         <a href="#rid82">
          82
         </a>
         ]. The overall incidence of pneumonitis was higher with the pemetrexed-cisplatin group than with etoposide-cisplatin (17 versus 11 percent), although the incidence of pneumonitis grade ≥3 was not increased (1.8 versus 2.6 percent)  (
         <a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">
          "Management of stage III non-small cell lung cancer", section on 'Choice of chemotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune checkpoint inhibitors
         </strong>
         – Immune checkpoint inhibitors (ICIs) are commonly used in lung cancer and other malignancies, but are associated with an inherent risk of ICI-associated pneumonitis of up to 19 percent [
         <a href="#rid83">
          83
         </a>
         ] as well as a possible increased risk of RILI. Teams caring for patients receiving ICI and radiotherapy should remain vigilant for symptoms of RILI and counsel patients regarding pneumonitis risks along with the associated benefits of ICI therapy. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Pneumonitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The potentiation of radiation pneumonitis by immunotherapy remains controversial. Although some retrospective studies have suggested increased risk of radiation injury with immunotherapy, data from immunotherapy trials do not show large differences in severe RILI [
         <a href="#rid84">
          84-87
         </a>
         ]. There is also clinical equipoise about the interaction of targeted agents such as tyrosine kinase inhibitors (TKIs) with radiotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A pooled analysis of 16,835 patients from 68 trials who received immunotherapy within 90 days of radiation therapy showed no increased risk of adverse events (including pneumonitis) with immunotherapy [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The PACIFIC study, which randomized patients receiving the ICI,
         <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">
          durvalumab
         </a>
         , or placebo following definitive chemotherapy and radiation for stage III NSCLC, showed a significant survival advantage to ICI therapy for these patients [
         <a href="#rid84">
          84
         </a>
         ]. While the overall risk of any pneumonitis was higher with durvalumab (33.9 versus 24.8 percent), the incidence of clinically important Grade 3 or 4 events  (
         <a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">
          table 2
         </a>
         ) was similar (3.4 versus 2.6 percent), suggesting the use of ICI following chemoradiotherapy was relatively safe. (See
         <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">
          "Management of stage III non-small cell lung cancer", section on 'Incorporation of immunotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In contrast, a meta-analysis of EGFR TKI and concurrent chemoradiotherapy for unresectable NSCLC noted a possible increased risk of pneumonitis, although this was not significant (OR 1.76, 95% CI 0.98-3.15) [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A subsequent prospective trial of 133 patients with widely metastatic NSCLC who received palliative radiotherapy and concurrent EGFR TKI noted a 6 percent incidence of grades 3 to 4 pneumonitis  (
         <a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid89">
          89
         </a>
         ]. This is consistent with data indicating an increased risk of recall pneumonitis with earlier generation TKI agents; an overlap time of &gt;20 days may be a relevant risk factor [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1572159951">
         <span class="h2">
          Interstitial lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the most significant predictors of RILI is the presence of baseline ILD [
         <a href="#rid92">
          92,93
         </a>
         ]. ILD has been associated with a significant risk of respiratory failure or death from radiation pneumonitis [
         <a href="#rid92">
          92,94
         </a>
         ]. In one large single-center series, 39 of 537 patients treated with SBRT had preexisting ILD (13 with usual interstitial pneumonitis [UIP] and 24 with possible UIP) [
         <a href="#rid95">
          95
         </a>
         ]. The rate of symptomatic radiation pneumonitis was much higher (20.5 versus 5.8 percent) in the patients with ILD, who also accounted for two out of three deaths due to RILI. A high rate of mortality was confirmed in a multicenter cohort reporting 17 fatal cases of radiation pneumonitis (6.9 percent mortality) among 242 patients with early-stage lung cancer and preexisting ILD treated with SBRT. The biggest risk factor for fatal radiation pneumonitis was the dose of radiation received by normal lung (mean percentage normal lung volume receiving more than 20 Gy (V
         <sub>
          20
         </sub>
         ) &gt;10 percent) [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
         In a 2020 consensus statement, the International Association for the Study of Lung Cancer (IASLC) emphasized not only identification of subclinical ILD, but also careful risk-benefit assessment of radiation therapy in the context of progressive fibrotic interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF) [
         <a href="#rid97">
          97
         </a>
         ]. Patients with more advanced disease and poorer prognosis due to ILD likely have higher risk of severe RILI and a lower likelihood of benefit from radiation treatment. For patients with IPF, the use of validated prognostic scores (eg, the ILD-GAP score  (
         <a class="graphic graphic_table graphicRef114397" href="/z/d/graphic/114397.html" rel="external">
          table 4
         </a>
         )) may inform individualized discussions about the risks and benefits of radiotherapy.
        </p>
        <p class="headingAnchor" id="H108098608">
         <span class="h2">
          Prior radiation (recall)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation recall pneumonitis can occur when certain chemotherapy agents (eg,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         ,
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         ) and immune checkpoint inhibitors are administered to a patient who has received prior radiation therapy to the lung [
         <a href="#rid79">
          79,98-107
         </a>
         ]. Patients typically develop symptoms such as cough and dyspnea associated with radiographic opacities that conform to the prior radiation field.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior thoracic irradiation, volume loss due to lung collapse, younger age, smoking history, poor pretreatment performance status, poor pretreatment lung function, chronic obstructive pulmonary disease (COPD), female sex, endocrine therapy for breast cancer, and glucocorticoid withdrawal during radiotherapy have all been reported to influence the risk of radiation pneumonitis [
         <a href="#rid11">
          11,68,73,98,108-110
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking
         </strong>
         – Smoking history has been reported as a risk factor for RILI in some studies [
         <a href="#rid108">
          108,109
         </a>
         ]. However, one retrospective study of 405 female smokers and nonsmokers who underwent radiotherapy for treatment of breast or esophageal cancer found that none of the actively smoking patients developed RILI [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These findings are intriguing because other inflammatory lung diseases with a predominance of lymphocytes, such as hypersensitivity pneumonitis, are also uncommon in smokers. (See
         <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis", section on 'Effect of cigarette smoking'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COPD
         </strong>
         – Data are conflicting regarding the effect of COPD on the risk of radiation pneumonitis [
         <a href="#rid98">
          98,112-118
         </a>
         ]. One prospective single-center study of 153 patients with lung cancer demonstrated pulmonary emphysema as an independent risk factor for the development of symptomatic (grade ≥2) or severe (≥3) radiation pneumonitis  (
         <a class="graphic graphic_table graphicRef61493" href="/z/d/graphic/61493.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid117">
          117
         </a>
         ]. Similarly, among 80 patients with stage III NSCLC treated with cisplatin-based chemotherapy and irradiation, COPD was associated with an increased frequency of radiation pneumonitis and an increased risk of more severe pneumonitis [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, a single course of lung SBRT in stage I NSCLC has not been associated with a decrement in lung function in patients with poor baseline pulmonary function and COPD in prospective trials [
         <a href="#rid116">
          116
         </a>
         ]. In addition, one retrospective study found that patients with more severe COPD developed less symptomatic radiation pneumonitis than those with more normal lungs [
         <a href="#rid112">
          112
         </a>
         ]. While this could be confounded by the lack of randomization and difficulties with scoring of radiation pneumonitis due to the similarity of symptoms of COPD exacerbation and radiation pneumonitis, it is possible that the less diseased lungs tolerate radiation less well than those afflicted by COPD [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endocrine therapy for breast cancer
         </strong>
         – Some studies suggest that concurrent (but not sequential) use of
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         may increase the rate of RILI in females treated for breast cancer; however, this has not been a consistent finding across studies [
         <a href="#rid119">
          119
         </a>
         ]. In general, higher rates of symptomatic (grade 2 or higher) pneumonitis have not been seen. In contrast, the frequency of radiation-induced organizing pneumonia may be increased by concurrent endocrine therapy. For example, in one retrospective series of 702 females with breast cancer who received breast conserving therapy, organizing pneumonia was associated with concurrent radiation and endocrine therapy (6.2 versus 1.1 percent, OR 3.05, 95% CI 1.09-8.54) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic background
         </strong>
         – Animal and human studies suggest that there is a significant role for genetic susceptibility to irradiation injury [
         <a href="#rid22">
          22-24
         </a>
         ]. Contemporary studies of patients receiving irradiation for breast cancer have shown suggestive associations between certain genetic factors and development of fibrosis following irradiation [
         <a href="#rid26">
          26,27
         </a>
         ]. Among 137 patients receiving irradiation for non-small cell or small cell lung cancer, presence of a single nucleotide polymorphism in the methylene tetrahydrofolate reductase gene (
         <em>
          MTHFR
         </em>
         ; rs1801133) was associated with an increased risk of radiation pneumonitis [
         <a href="#rid28">
          28
         </a>
         ]. In separate studies of lung cancer patients, polymorphisms of the ataxia telangiectasia mutated (
         <em>
          ATM
         </em>
         ) gene and TGF-beta gene were associated with an increased risk of radiation pneumonitis [
         <a href="#rid29">
          29,30,38
         </a>
         ]. In contrast, single nucleotide polymorphisms of the heat shock protein pathway member HSPB1 have been associated with lower rates of radiation pneumonitis in a retrospective study [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2675991578">
         <span class="h1">
          TYPICAL DISEASE COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathologic and clinical changes in the lung following irradiation may be understood as an evolution through five phases, although these phases are not always clinically apparent  (
         <a class="graphic graphic_table graphicRef140109" href="/z/d/graphic/140109.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid120">
          120
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immediate phase
         </strong>
         – The immediate phase begins within hours to days following radiation exposure and is generally clinically asymptomatic. Pathologically, it is characterized by hyperemic, congested mucosa with leukocytic infiltration and increased capillary permeability, resulting in localized pulmonary edema. An exudative alveolitis follows, accompanied by tracheal bronchial hypersecretion and degenerative changes in the alveolar epithelium and endothelium. Type I alveolar epithelial cells (pneumocytes) are sloughed, and alveolar surfactant levels are increased [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Latent phase
         </strong>
         – During the next two to three weeks, thick secretions frequently accumulate in irradiated lung due to an increase in the number of goblet cells combined with ciliary dysfunction. These changes can result in cough for those with large radiation ports, but they are generally clinically silent. Outside of the radiation field, an asymptomatic CD4+ lymphocytic alveolitis consistent with a mild hypersensitivity pneumonitis-like reaction commonly appears throughout the lung, including on the contralateral side [
         <a href="#rid121">
          121
         </a>
         ]. This phenomenon does not predict progression to clinically significant radiation pneumonitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute exudative phase
         </strong>
         – The acute exudative phase occurs 3 to 12 weeks following exposure. Clinical manifestations of radiation pneumonitis most frequently occur in this phase and include [
         <a href="#rid122">
          122,123
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fevers (typically mild)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dyspnea with exertion or breathlessness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cough, generally nonproductive
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest pain, frequently pleuritic, but may also be substernal (esophagitis or pleuritis may contribute)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malaise and weight loss
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On physical examination, crackles and a pleural rub may be heard over the affected area, and small pleural effusions are detectable in about 10 percent of patients. In contrast to malignant effusions, radiation-induced effusions do not increase in size after a period of observed stability. There may also be signs of skin erythema over the radiation port, but these do not correlate with radiation pneumonitis presence or severity. Frank signs of severe pulmonary dysfunction (tachypnea, cyanosis, pulmonary hypertension) occur in the most severe cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pathologically, this phase consists of sloughing of endothelial and epithelial cells with narrowing of the pulmonary capillaries and microvascular thrombosis. Hyaline membranes form due to the alveolar pneumocyte desquamation and subsequent leakage of a fibrin-rich exudate into the alveoli. Giant cells may be seen along the endothelium, and type II pneumocytes become hyperplastic with marked atypia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermediate phase
         </strong>
         – The intermediate phase is characterized by resolution of the acute exudative process, usually accompanied by a gradual diminishment in clinical symptoms, if present. For most patients, there will be resolution of the alveolar exudate and dissolution of the hyaline membranes throughout much of the radiation port. However, more pathologic healing frequently occurs in the most injured tissue and results in fibroblast migration and proliferation in the alveolar walls and spaces, collagen deposition, and thickening of the interstitium [
         <a href="#rid124">
          124,125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation fibrosis
         </strong>
         – This final phase may occur as early as six months and can progress over years, and its estimated incidence is between five and fifteen percent [
         <a href="#rid126">
          126,127
         </a>
         ]. Radiation fibrosis follows from fibroblast-predominant healing in the intermediate phase, and it is characterized by increasing collagen and myofibroblast proliferation in both interstitial and alveolar spaces. Some patients present clinically during this phase of injury, most frequently with cough and dyspnea rather than other manifestations. Fibrotic regions will demonstrate dry crackles on exam. The fibrotic process results in focal loss of lung volume, which is frequently accompanied by traction bronchiectasis. Bronchiectatic areas may also be complicated by chronic infection, especially in patients who are immunocompromised due to their cancer treatments. (See
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Less typically, a secondary organizing pneumonia may be seen approximately 3 to 17 months after radiotherapy [
         <a href="#rid12">
          12,13,128,129
         </a>
         ]. Organizing pneumonia is characterized clinically by the same symptoms of radiation pneumonitis, but there is generally radiographic involvement of areas outside the radiation field, often including the contralateral lung. Histopathologically, there is a proliferation of fibroblastic granulation tissue within the alveolar ducts and alveoli without disruption of the lung architecture. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Histopathologic diagnosis of organizing pneumonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         RILI should be suspected when a patient who has undergone thoracic irradiation develops symptoms or signs, such as dyspnea, cough, fever, malaise, auscultatory crackles, or a pleural rub, in the weeks to months after radiation therapy. The evaluation is designed to assess the severity of respiratory impairment, determine the correspondence of radiographic changes with the radiation therapy portal to exclude other possible causes of the findings, such as infection, thromboembolic disease, drug-induced pneumonitis, spread of the underlying malignancy, tracheoesophageal fistula, or exacerbation of underlying chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or heart failure [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest imaging is the cornerstone of the diagnostic evaluation in patients who present with typical clinical manifestations. Radiographic abnormalities within the radiation port at the appropriate time following thoracic radiation are highly suspicious.
        </p>
        <p class="headingAnchor" id="H180831">
         <span class="h3">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiographs are often obtained early upon patient presentation prior to computed tomography (CT) imaging. Typical findings vary by phase of disease  (
         <a class="graphic graphic_table graphicRef140109" href="/z/d/graphic/140109.html" rel="external">
          table 5
         </a>
         ). Perivascular haziness is an early finding, which often progresses to patchy alveolar filling densities in the radiation port during the acute exudative phase. Chronic radiation fibrosis is characterized by volume loss with coarse reticular or dense opacities. A
         <strong>
          straight-line
         </strong>
         effect, in which opacities do not conform to anatomical units but rather to the confines of the radiation port, is virtually diagnostic of RILI. However, obvious straight lines on chest radiograph are now seen less frequently due to newer radiation techniques that involve three-dimensional (3D) modeling. (See
         <a class="local">
          'Method of irradiation'
         </a>
         above.)
        </p>
        <p>
         Small pleural effusions and rib fractures may be seen, but lymphadenopathy does not generally occur. Radiographic abnormalities outside of the irradiation port may be seen [
         <a href="#rid109">
          109,128
         </a>
         ]. This may be due to radiation scatter, lymphatic obstruction, immunologic (hypersensitivity-like) mechanisms, or secondary organizing pneumonia.
        </p>
        <p class="headingAnchor" id="H180885">
         <span class="h3">
          Chest computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest CT is more sensitive than the chest radiograph and allows better comparison to the radiation port for evaluation of likely radiation injury. Cross-sectional imaging is appropriate for any patient with suspected radiation pneumonitis. The CT scan may take the form of a CT pulmonary angiogram (CTPA) to exclude pulmonary thromboembolism if this is also in the differential. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         .)
        </p>
        <p>
         The key step in the evaluation of radiation pneumonitis is comparison of pretreatment CT images, containing irradiation dosimetric information, with diagnostic CT images obtained after development of symptoms. Lung involvement in CT images of radiation pneumonitis typically aligns closely with the irradiated area. Comparisons between pre- and posttreatment images may sometimes be difficult due to tumor growth or shrinkage, changes in depth of respiration, and the complexity of the radiation port, but use of specialized software may aid in this process [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
         Similar to the plain chest radiograph, the CT scan appearance of radiation pneumonitis correlates with the phase of lung injury, although a given patient may present at any one of the phases [
         <a href="#rid131">
          131,132
         </a>
         ]. The radiographic phases are different than the clinicopathologic phases of disease  (
         <a class="graphic graphic_table graphicRef140109" href="/z/d/graphic/140109.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial phase
         </strong>
         – The initial radiographic phase, which corresponds to the acute and early intermediate phases pathologically, occurs three to five months after completion of radiation therapy and shows ground-glass attenuation within the area of irradiated lung.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organizing phase
         </strong>
         – The organizing phase follows the initial phase and can last up to six months. The ground-glass attenuations morph patchy areas of consolidation, which in turn coalesce to form a relatively sharp edge that conforms to the radiation therapy portals rather than anatomic structures. These patchy areas sometimes appear nodular.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrotic phase
         </strong>
         – Over several months following the organizing phase, opacities may resolve with minimal scarring or may become fibrotic. Radiation fibrosis is characterized on CT by linear opacities (scarring) or an area of dense consolidation and volume loss. The area of consolidation typically corresponds to the radiation port, although conformal and stereotactic treatment strategies do not yield the classic "straight line" radiographic finding, as described above. (See
         <a class="local">
          'Chest radiograph'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         The exact radiographic pattern of lung involvement is influenced by the specific radiation therapy technique used, such as limited tangential beams (eg, for breast cancer treatment), conformal therapy (eg, for bronchogenic cancer), and complex portal arrangements (eg, margins around primary bronchogenic carcinoma and around regional lymph nodes) [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/789.html" rel="external">
          "Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Intensity-modulated radiation therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Stereotactic radiation therapy techniques'
         </a>
         .)
        </p>
        <p>
         The less typical pattern of secondary organizing pneumonia may occur 3 to 17 months following radiation therapy and is characterized most typically by dense peripheral consolidations outside of the radiation field and even in the contralateral lung. Additional potential radiographic findings in organizing pneumonia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Chest imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs) are most helpful in excluding obstructive pulmonary processes and in characterizing the severity of respiratory impairment. Typically, spirometry (before and after bronchodilator), lung volumes, diffusing capacity for carbon monoxide (DLCO), and a six-minute walk test with oximetry are obtained as a baseline prior to radiation therapy in patients expected to have large volumes of lung irradiated.
        </p>
        <p>
         In patients with RILI, PFTs generally demonstrate a reduction in lung volumes (total lung capacity [TLC], forced vital capacity [FVC], residual volume [RV]), diffusing capacity, and lung compliance [
         <a href="#rid11">
          11,133,134
         </a>
         ]. For patients with large areas affected, tidal volumes are also decreased and the respiratory rate elevated. As with other causes of interstitial or fibrotic lung disease, ambulatory or resting pulse oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) may be reduced. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">
          "Measures of oxygenation and mechanisms of hypoxemia"
         </a>
         .)
        </p>
        <p>
         The diffusing capacity for carbon monoxide (DLCO or transfer factor) is usually depressed in patients with radiation-induced lung damage [
         <a href="#rid135">
          135
         </a>
         ], but this finding is nonspecific, as it can also be reduced in emphysema and ILD. One trial suggested that failure of the DLCO to increase from the nadir value following myeloablative chemotherapy was more closely associated with the risk of progressive pulmonary dysfunction during subsequent irradiation than other parameters of lung function [
         <a href="#rid136">
          136
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main role for flexible fiberoptic bronchoscopy in patients with suspicion for RILI is to evaluate for infection, bleeding, drug hypersensitivity, or spread of the underlying malignancy. Bronchoscopy with bronchoalveolar lavage (BAL) is performed in the majority of patients but can be deferred in patients with typical clinical and radiographic findings. Transbronchial biopsy specimens may sometimes be useful for assessment of infection or lymphangitic spread of tumor in cases that are clinically atypical for RILI, but the size of the specimens is usually too small to establish a diagnosis of radiation pneumonitis. (See
         <a class="medical medical_review" href="/z/d/html/4400.html" rel="external">
          "Flexible bronchoscopy in adults: Indications and contraindications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         BAL fluid findings in radiation pneumonitis are not specific but usually show increased leukocytes with a lymphocytic predominance, as expected based on increased lymphocyte numbers after radiation injury [
         <a href="#rid137">
          137,138
         </a>
         ]. The majority of BAL lymphocytes postirradiation are CD4+ and are activated. The number of neutrophils, eosinophils, and macrophages may also be increased, but a predominance of neutrophils or eosinophils would be unusual.
        </p>
        <p>
         Tissue specimens via transbronchial biopsies are too small to establish a diagnosis of RILI. They are only occasionally used to rule out specific infections or lymphangitic spread of tumor in cases that are clinically atypical for RILI. (See
         <a class="medical medical_review" href="/z/d/html/4400.html" rel="external">
          "Flexible bronchoscopy in adults: Indications and contraindications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1221170830">
         <span class="h2">
          Tests of low utility
         </span>
        </p>
        <p class="headingAnchor" id="H3736493923">
         <span class="h3">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         No commonly employed laboratory test identifies the development of radiation pneumonitis. Nonspecific signs of inflammation are frequently present, including low-grade peripheral blood polymorphonuclear leukocytosis and modest elevations of sedimentation rate, serum lactic dehydrogenase (LDH), and C-reactive protein [
         <a href="#rid139">
          139
         </a>
         ]. Evaluation typically includes work-up for infection, heart failure, and bleeding.
        </p>
        <p class="headingAnchor" id="H2408645965">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of RILI is usually based on a combination of typical symptoms (eg, cough, dyspnea, and sometimes fever), timing, dose, and location of radiation therapy, compatible imaging findings, and exclusion of other causes, such as infection including the novel coronavirus SARS-CoV-2 (COVID-19), heart failure, pulmonary embolism, drug-induced pneumonitis, bleeding, and progression of the primary tumor. For the majority of patients with RILI, the opacities on imaging conform to the radiation ports. An exception is radiation-associated organizing pneumonia, which generally occurs in patients with irradiation for breast or mediastinal malignancy rather than lung cancer. Lung biopsy is rarely required for diagnosis of RILI, usually only when an alternative diagnosis cannot be excluded. (See
         <a class="local">
          'Typical disease course'
         </a>
         above and
         <a class="local">
          'Imaging studies'
         </a>
         above.)
        </p>
        <p>
         Radiation pneumonitis can be graded in several ways to reflect severity of symptoms and radiographic changes, although grading is used more for research purposes than routine clinical care [
         <a href="#rid140">
          140,141
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2757688561">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of radiation pneumonitis most commonly includes infection, thromboembolic disease, drug-induced pneumonitis, spread of the underlying malignancy, and acute exacerbation of cardiopulmonary disease (chronic obstructive pulmonary disease [COPD], interstitial lung disease [ILD], or heart failure). Viral pneumonias, including SARS-CoV-2 pneumonia, can be particularly challenging to distinguish from radiation pneumonitis if they occur within three months of radiation therapy. (See
         <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">
          "Approach to the immunocompromised patient with fever and pulmonary infiltrates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention"
         </a>
         .)
        </p>
        <p>
         For patients with chest discomfort, but without new lung parenchymal changes on chest imaging, potential causes include pericarditis, esophagitis, and early radiation pneumonitis that has not yet manifested in radiographic abnormalities.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         No prospective controlled studies have evaluated the efficacy of therapies for radiation pneumonitis in humans. Nevertheless, many experts recommend the use of glucocorticoids for symptomatic patients with a subacute onset of RILI [
         <a href="#rid11">
          11,142
         </a>
         ]. Patients who have established fibrosis due to prior irradiation are unlikely to benefit from glucocorticoid therapy [
         <a href="#rid123">
          123
         </a>
         ]. It is unknown whether drugs that inhibit collagen synthesis and deposition will slow further fibrosis. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3847114198">
         <span class="h2">
          Supportive care, for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care may include antitussive therapy, supplemental oxygen, and treatment of comorbid cardiopulmonary diseases that may contribute to symptoms. Antitussive therapy, such as
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         or
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         , may provide symptomatic relief of cough, although formal study in the setting of RILI is lacking. (See
         <a class="medical medical_review" href="/z/d/html/1428.html" rel="external">
          "Evaluation and treatment of subacute and chronic cough in adults", section on 'Unexplained chronic cough'
         </a>
         .)
        </p>
        <p>
         Therapy with supplemental oxygen is indicated for patients with a resting pulse oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) ≤88 percent, although this oxygen need may be transient for patients presenting in the acute exudative phase. (See
         <a class="local">
          'Typical disease course'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3294704977">
         <span class="h2">
          Patients with minimal or no symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are asymptomatic or have minimal symptoms may experience a spontaneous resolution, so we do not initiate treatment unless symptoms become bothersome or pulmonary function declines by more than 10 percent. We continue to monitor these patients at regular intervals with assessment of symptoms, chest radiography, and pulmonary function, as indicated. Antitussive agents and bronchodilators are occasionally helpful in patients with mild to moderate symptoms.
        </p>
        <p>
         Alternatively, improvement in mild symptoms has been described with high-dose inhaled glucocorticoids, which are probably equivalent to low-dose oral corticosteroid therapy. In a single-center study, 24 patients with pneumonitis following irradiation for lung cancer were initially treated with high-dose inhaled glucocorticoids (
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         800 mcg twice a day) for 14 days [
         <a href="#rid143">
          143
         </a>
         ]. Eighteen patients responded to inhaled budesonide, while six did not improve within two weeks and needed to be transitioned to oral glucocorticoids. Median treatment duration in the inhaled steroid group was 8.4 months.
        </p>
        <p class="headingAnchor" id="H934412575">
         <span class="h2">
          Symptomatic patients with subacute radiation pneumonitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest the use of oral glucocorticoids for patients with a subacute onset of radiation pneumonitis, moderate to severe symptoms (eg, dyspnea that interferes with activities of daily living), or evidence of impaired respiratory function. This approach, which is in accordance with other expert advice [
         <a href="#rid11">
          11,142
         </a>
         ], is based on both clinical experience and multiple reports of a prompt response to oral glucocorticoid therapy.
        </p>
        <p>
         We treat with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.75 mg/kg ideal body weight (approximately 40 to 60 mg/day) for two to four weeks followed by a taper over 3 to 12 weeks, although the guidelines for tapering are poorly defined [
         <a href="#rid11">
          11
         </a>
         ]. We monitor symptoms closely during tapering. If the patient experiences relapse of symptoms, we return to full dose for two weeks and attempt a slower taper, particularly when the dose is 20 mg per day or less.
        </p>
        <p>
         We suggest prophylaxis for
         <em>
          Pneumocystis
         </em>
         pneumonia when the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose exceeds 20 mg a day for more than a month [
         <a href="#rid144">
          144
         </a>
         ]. Steps to monitor and prevent the various adverse effects associated with systemic glucocorticoids are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'General treatment considerations and monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
         For patients who do not tolerate or do not respond to glucocorticoid therapy, use of
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         have been reported, but are not frequently used [
         <a href="#rid145">
          145,146
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2679292403">
         <span class="h2">
          Patients with radiation-associated organizing pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with radiation-associated organizing pneumonia OP based on clinical and radiographic features or increased suspicion due to recurrent disease relapse upon
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         tapering, we follow the treatment approach usually used for cryptogenic organizing pneumonia (COP). (See
         <a class="local">
          'Typical disease course'
         </a>
         above and
         <a class="local">
          'Chest computed tomography'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2611074847">
         <span class="h2">
          Patients with radiation-induced pulmonary fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no established guidelines for the management of radiation-induced lung fibrosis. There is interest in studying antifibrotic therapy, such as
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         , for progressive fibrosing disease, but there are limited data to support efficacy. Two small studies have suggested that the use of the TKI nintedanib may prevent radiation pneumonitis and/or decrease the risk of recurrence of radiation pneumonitis in combination with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         [
         <a href="#rid147">
          147,148
         </a>
         ]. However, more definitive data are needed before such protocols are adopted for routine clinical use. Inflammation is not prominent and anti-inflammatory therapy, specifically glucocorticoids, should be avoided to prevent unnecessary side effects.
        </p>
        <p>
         Supportive care such as oxygen supplementation, pulmonary rehabilitation, mucociliary clearance, and vaccinations against influenza and pneumococcus should be instituted, as appropriate. (See
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Airway clearance therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Significant improvements in the perfusion and ventilation of radiation-injured lung tissue frequently occur 3 to 18 months after radiation therapy during the organizing phase, often leading to reduced dyspnea, hypoxemia, and cough. (See
         <a class="local">
          'Typical disease course'
         </a>
         above.)
        </p>
        <p>
         After 18 months, however, radiation fibrosis of the most affected areas is established, and further improvement is unusual [
         <a href="#rid133">
          133,149
         </a>
         ]. Radiation fibrosis can progress in some patients to include other previously noninjured areas of lung. This progression is thought to be related to the pathogenesis of other fibrotic lung diseases, but it is not well understood. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis", section on 'Progression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27073896">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best-known strategies for reducing RILI are those that limit the radiation dose and volume of normal lung tissue irradiated. As noted above, a panel of physicians and physicists concluded that for routine clinical practice, the mean lung dose (MLD) should be kept below 20 Gy, when possible, and the volume of lung receiving more than 20 Gy (V
         <sub>
          20
         </sub>
         ) should be kept below 35 to 40 percent to keep the risk of pneumonitis ≤20 percent [
         <a href="#rid39">
          39
         </a>
         ]. No specific pharmacotherapies have been well-established to prevent radiation injury in the lung. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         Several routinely used therapies, including glucocorticoids, antibiotics, and heparin, have been studied in the hope that they might protect against RILI, but none have been effective in this role [
         <a href="#rid5">
          5,108,129,150-152
         </a>
         ].
        </p>
        <p>
         Several other experimental agents have also been assessed for a potential role in the prevention of RILI and radiation-induced fibrosis in other organs. These include
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         and
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          amifostine
         </a>
         , which both showed benefit in early studies that have not been successfully replicated [
         <a href="#rid146">
          146,153
         </a>
         ]. Angiotensin-converting enzyme (ACE) inhibitors have also showed a protective effect in preclinical models and a retrospective series [
         <a href="#rid154">
          154,155
         </a>
         ], but trial data are lacking. (See
         <a class="medical medical_review" href="/z/d/html/7055.html" rel="external">
          "Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"
         </a>
         .)
        </p>
        <p>
         In China, Aidi (Z52020236, China Food and Drug Administration [CFDA]), an injectable agent composed of the extracts from Astragalus, Eleutherococcus senticosus, Ginseng, and
         <a class="drug drug_general" data-topicid="8838" href="/z/d/drug information/8838.html" rel="external">
          Cantharidin
         </a>
         , is often administered. Although a meta-analysis of many small studies shows a potential reduced risk of RILI after pretreatment with Aidi [
         <a href="#rid156">
          156
         </a>
         ], lack of availability or evaluation outside of China limits its use.
        </p>
        <p class="headingAnchor" id="H181566">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who undergo thoracic irradiation for the treatment are at risk for RILI, including pneumonitis and fibrosis. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Many factors affect the risk for RILI, including the method, dose, and frequency of irradiation, the volume of irradiated lung, associated chemotherapy, comorbid interstitial lung disease (ILD), and the genetic background of the patient. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease course and findings
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Disease course
         </strong>
         – Symptoms caused by radiation pneumonitis usually develop in the acute exudative phase, approximately 3 to 12 weeks following irradiation. The injury often improves over the subsequent intermediate phase, but 5 to 15 percent of patients develop radiation fibrosis in the regions of greatest injury after 6 to 12 months  (
         <a class="graphic graphic_table graphicRef140109" href="/z/d/graphic/140109.html" rel="external">
          table 5
         </a>
         ). Typical symptoms for both radiation pneumonitis and radiation fibrosis include dyspnea, cough, chest pain, fever, and malaise. (See
         <a class="local">
          'Typical disease course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging characteristics
         </strong>
         – Compared with radiographs, Chest CT provides much better evaluation of subtle changes and allows closer comparison between radiographic abnormalities and the radiation therapy ports or dosimetry modeling. In the acute exudative phase, chest CT may show patchy alveolar ground-glass or consolidative opacities. Over the ensuing weeks to months, these consolidations coalesce. A straight-line effect, in which abnormalities conform to within radiation port edges rather than anatomical units, is diagnostic of RILI, but may not occur in patients treated with conformal and stereotactic radiation. Chronic changes are characterized by volume loss with coarse reticular or dense opacities. (See
         <a class="local">
          'Imaging studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of radiation pneumonitis is based on correlations between the onset of symptoms and signs, the timing of irradiation, the pattern of radiographic changes, and the radiation therapy portal. Careful exclusion of other possible diagnoses, such as infection, thromboembolic disease, drug-induced pneumonitis, pericarditis, esophagitis, tumor progression, or tracheoesophageal fistula, is required. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are asymptomatic or have minimal symptoms, we provide supportive care only (eg, antitussives). (See
         <a class="local">
          'Supportive care, for all patients'
         </a>
         above and
         <a class="local">
          'Patients with minimal or no symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with moderate to severe symptoms or change in pulmonary function four weeks to six months after initiation of radiation therapy, we suggest administering
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         rather than observation alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We typically use 0.75 mg/kg up to 60 mg/day for two to four weeks, followed by a gradual taper based on patient response . (See
         <a class="local">
          'Symptomatic patients with subacute radiation pneumonitis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'General treatment considerations and monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with radiation-associated organizing pneumonia based on disease time-course, typical radiographic pattern, and/or characteristic-appearing relapse during tapering of oral glucocorticoids, we advise following the treatment approach used for cryptogenic organizing pneumonia (COP). (See
         <a class="local">
          'Patients with radiation-associated organizing pneumonia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who have established fibrosis due to prior irradiation are unlikely to benefit from glucocorticoid therapy. Other antifibrotic therapies have not been well studied in these patients. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Dyspnea and hypoxemia frequently decrease over 3 to 18 months due to improvements in perfusion and ventilation of radiation-injured lung tissue over this timeframe. Subsequent improvement is unusual.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1562450896">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William Merrill, MD and Kenneth R Olivier, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bergonie, J, Teissier, J. Rapport sur l'action des rayons X sur la tuberculose. Arch Electr Med 1898; 6:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans, WA, Leucutia, T. Intrathoracic changes induced by heavy irradiation. AJR 1925; 13:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abratt RP, Morgan GW. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 2002; 35:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coggle JE, Lambert BE, Moores SR. Radiation effects in the lung. Environ Health Perspect 1986; 70:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995; 31:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molls M, Herrmann Th, Steinberg F, Feldmann HJ. Radiopathology of the lung: experimental and clinical observations. Recent Results Cancer Res 1993; 130:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Movsas B, Raffin TA, Epstein AH, Link CJ Jr. Pulmonary radiation injury. Chest 1997; 111:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocak Z, Evans ES, Zhou SM, et al. Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys 2005; 62:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012; 82:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bledsoe TJ, Nath SK, Decker RH. Radiation Pneumonitis. Clin Chest Med 2017; 38:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katayama N, Sato S, Katsui K, et al. Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Int J Radiat Oncol Biol Phys 2009; 73:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takigawa N, Segawa Y, Saeki T, et al. Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys 2000; 48:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogo E, Komaki R, Abe T, et al. The clinical characteristics and non-steroidal treatment for radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Radiother Oncol 2010; 97:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murofushi KN, Oguchi M, Gosho M, et al. Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age. Radiat Oncol 2015; 10:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2015; 92:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998; 41:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazeron R, Etienne-Mastroianni B, Pérol D, et al. Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2010; 77:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Williams J, Ding I, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002; 12:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Rubin P, Williams J, et al. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2001; 49:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995; 33:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haston CK, Begin M, Dorion G, Cory SM. Distinct loci influence radiation-induced alveolitis from fibrosing alveolitis in the mouse. Cancer Res 2007; 67:10796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelsey CR, Rosenstein BS, Marks LB. Predicting toxicity from radiation therapy--it's genetic, right? Cancer 2012; 118:3450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen J, Liu H, Wang Q, et al. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur J Cancer 2014; 50:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuptsova N, Chang-Claude J, Kropp S, et al. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 2008; 122:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suga T, Ishikawa A, Kohda M, et al. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007; 69:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giotopoulos G, Symonds RP, Foweraker K, et al. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 2007; 96:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mak RH, Alexander BM, Asomaning K, et al. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer 2012; 118:3654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Yang M, Bi N, et al. ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 2010; 77:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong H, Liao Z, Liu Z, et al. ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anscher MS, Marks LB, Shafman TD, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao L, Sheldon K, Chen M, et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 2008; 59:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adawi A, Zhang Y, Baggs R, et al. Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol 1998; 89:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosiello RA, Merrill WW, Rockwell S, et al. Radiation pneumonitis. Bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am Rev Respir Dis 1993; 148:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy S, Salerno KE, Citrin DE. Biology of Radiation-Induced Lung Injury. Semin Radiat Oncol 2021; 31:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno M, Aristu J, Ramos LI, et al. Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer. Clin Transl Oncol 2007; 9:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen S, Zhou S, Zhang J, et al. A neural network model to predict lung radiation-induced pneumonitis. Med Phys 2007; 34:3420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009; 27:3370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010; 76:S70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76:S10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lind PA, Marks LB, Hardenbergh PH, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lingos TI, Recht A, Vicini F, et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimsey FC, Mendenhall NP, Ewald LM, et al. Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation. Cancer 1994; 73:2549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005; 235:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers SA, Wallington MM. Total body irradiation and pneumonitis risk: a review of outcomes. Br J Cancer 2004; 90:2080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998; 42:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fay M, Tan A, Fisher R, et al. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boonyawan K, Gomez DR, Komaki R, et al. Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys 2018; 101:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roach M 3rd, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995; 13:2606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi H, Uno T, Isobe K, et al. Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer. Jpn J Clin Oncol 2010; 40:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JD, Hope A, El Naqa I, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 2007; 69:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chun SG, Hu C, Choy H, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 2017; 35:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pang Q, Wei Q, Xu T, et al. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013; 85:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okubo K, Gotoh M, Asako M, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int 2017; 66:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma V, Shostrom VK, Zhen W, et al. Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis. Int J Radiat Oncol Biol Phys 2017; 97:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma V, Simone CB 2nd, Allen PK, et al. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017; 97:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Yorke ED, Li L, et al. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. Int J Radiat Oncol Biol Phys 2016; 95:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamashita H, Takahashi W, Haga A, Nakagawa K. Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol 2014; 6:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong FS, Moiseenko V, Zhao J, et al. Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? Int J Radiat Oncol Biol Phys 2021; 110:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma V, Shah C, Mehta MP. Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. Clin Breast Cancer 2016; 16:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011; 117:4707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. Radiat Oncol 2016; 11:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao Z, Lee JJ, Komaki R, et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018; 36:1813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu NY, DeWees TA, Voss MM, et al. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer. Clin Lung Cancer 2022; 23:e526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93:1806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang S, Liao Z, Wei X, et al. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 2008; 3:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mao J, Kocak Z, Zhou S, et al. The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. Int J Radiat Oncol Biol Phys 2007; 67:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003; 67:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbanic JJ, Lally B, Blackstock AW. "The best-laid plans ... often go awry ...". J Thorac Oncol 2009; 4:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. J Clin Oncol 2012; 30:e104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rengan R, Mick R, Pryma D, et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012; 7:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 2012; 51:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakravarthy A, Johnson D, Choy H. The role of radiation, with or without chemotherapy, in the management of NSCLC. Oncology (Williston Park) 1999; 13:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 2009; 4:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zinner RG, Komaki R, Cox JD, et al. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 73:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choy H, Jain AK, Moughan J, et al. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 2009; 4:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008; 26:2457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochstrasser A, Benz G, Joerger M, et al. Interstitial pneumonitis after treatment with pemetrexed: a rare event? Chemotherapy 2012; 58:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bischof M, Weber KJ, Blatter J, et al. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002; 52:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen AM, Czerminska M, Jänne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senan S, Brade A, Wang LH, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suresh K, Voong KR, Shankar B, et al. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. J Thorac Oncol 2018; 13:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaverdian N, Thor M, Shepherd AF, et al. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. Cancer Med 2020; 9:4622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys 2020; 108:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anscher MS, Arora S, Weinstock C, et al. Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database. JAMA Oncol 2022; 8:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li X, Wang F, Jia H, et al. Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. Future Oncol 2022; 18:3055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang XS, Bai YF, Verma V, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst 2023; 115:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia W, Gao Q, Wang M, et al. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Radiat Oncol 2021; 16:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang CL, Chen YW, Wu MH, et al. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. J Chin Med Assoc 2016; 79:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueki N, Matsuo Y, Togashi Y, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 2015; 10:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Senan S, Nossent EJ, et al. Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. Int J Radiat Oncol Biol Phys 2017; 98:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahig H, Filion E, Vu T, et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol 2016; 6:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glick D, Lyen S, Kandel S, et al. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT). Clin Lung Cancer 2018; 19:e219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onishi H, Yamashita H, Shioyama Y, et al. Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study. Cancers (Basel) 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman CD, Nijman SFM, Senan S, et al. A Primer on Interstitial Lung Disease and Thoracic Radiation. J Thorac Oncol 2020; 15:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma LD, Taylor GA, Wharam MD, Wiley JM. "Recall" pneumonitis: adriamycin potentiation of radiation pneumonitis in two children. Radiology 1993; 187:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarte S, Wagner K, Karstens JH, Bremer M. Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 2007; 183:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeter MD, Jänne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kataoka M, Kawamura M, Nishiyama Y, et al. [A case with delayed-onset radiation pneumonitis suspected to be induced by oral etoposide]. Nihon Igaku Hoshasen Gakkai Zasshi 1992; 52:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faiz SA, Balachandran DD, Bashoura L, Shannon VR. Pulmonary Radiation Recall Induced by Gemcitabine. Am J Respir Crit Care Med 2016; 194:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awad R, Nott L. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review. Asia Pac J Clin Oncol 2016; 12:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voong KR, Hazell SZ, Fu W, et al. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 2019; 20:e470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visy A, Bachelot T, Racadot S. Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus. Cancer Radiother 2019; 23:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioannidis G, Gkogkou P, Charalampous P, et al. Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy. Radiother Oncol 2014; 112:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000; 48:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998; 82:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatramani R, Kamath S, Wong K, et al. Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation. Int J Radiat Oncol Biol Phys 2013; 86:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson S, Bjermer L, Franzen L, Henriksson R. Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiother Oncol 1998; 49:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 2012; 141:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yirmibesoglu E, Higginson DS, Fayda M, et al. Challenges scoring radiation pneumonitis in patients irradiated for lung cancer. Lung Cancer 2012; 76:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adès J, Lempérière T. [Management of alcoholics by the general practitioner]. Rev Infirm 1979; 29:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012; 82:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanic S, Paulus R, Timmerman RD, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 2014; 88:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Z, Song X, Wu A, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep 2017; 7:2748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchiyama F, Nakayama H, Takeda Y, et al. Risk of radiation pneumonitis in patients with emphysema after stereotactic body radiotherapy for non-small cell lung cancer assessed by quantitative CT. Mol Clin Oncol 2020; 13:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varga Z, Cserháti A, Kelemen G, et al. Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2011; 80:1109.
          </a>
         </li>
         <li class="breakAll">
          Respiratory system. In: Clinical Radiation Pathology, Rubin P, Casseratt GW (Eds), WB Saunders, Philadelphia 1968. p.423.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín C, Romero S, Sánchez-Payá J, et al. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J 1999; 13:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977; 86:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abratt RP, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med 2004; 25:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epperly MW, Guo H, Gretton JE, Greenberger JS. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theise ND, Henegariu O, Grove J, et al. Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow. Exp Hematol 2002; 30:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25:3991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cella L, Liuzzi R, D'Avino V, et al. Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury. Acta Oncol 2014; 53:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbetter KR, Prakash UB, Tazelaar HD, Douglas WW. Radiation-induced pneumonitis in the "nonirradiated" lung. Mayo Clin Proc 1999; 74:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok E, Chan CK. Corticosteroids and azathioprine do not prevent radiation-induced lung injury. Can Respir J 1998; 5:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma DA, Senan S, Haasbeek CJ, et al. Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. Int J Radiat Oncol Biol Phys 2011; 80:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park KJ, Chung JY, Chun MS, Suh JH. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics 2000; 20:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004; 24:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borst GR, De Jaeger K, Belderbos JS, et al. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 2005; 62:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone B, Mangona VS, Johnson MD, et al. Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline Nor Post-SBRT Pulmonary Function Are Associated with Worse Overall Survival. J Thorac Oncol 2015; 10:1762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez Guerra JL, Gomez D, Zhuang Y, et al. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lind PA, Marks LB, Jamieson TA, et al. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue. Cancer 2002; 94:2821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan GW, Breit SN. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 1995; 31:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakayama Y, Makino S, Fukuda Y, et al. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1996; 34:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Huo B, Wu Q, et al. The role of procalcitonin in differential diagnosis between acute radiation pneumonitis and bacterial pneumonia in lung cancer patients receiving thoracic radiotherapy. Sci Rep 2020; 10:2941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kouloulias V, Zygogianni A, Efstathopoulos E, et al. Suggestion for a new grading scale for radiation induced pneumonitis based on radiological findings of computerized tomography: correlation with clinical and radiotherapeutic parameters in lung cancer patients. Asian Pac J Cancer Prev 2013; 14:2717.
          </a>
         </li>
         <li class="breakAll">
          Common Terminology Criteria for Adverse Events (CTCAE). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (Accessed on May 18, 2017).
         </li>
         <li class="breakAll">
          Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwartz MI, King, TE Jr. (Eds), People's Medical Publishing House-USA, Shelton, CT 2011. p.637.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkenberens C, Janssen S, Lavae-Mokhtari M, et al. Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience. Radiat Oncol 2016; 11:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross NJ, Narine KR, Wade R. Protective effect of corticosteroids on radiation pneumonitis in mice. Radiat Res 1988; 113:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozturk B, Egehan I, Atavci S, Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys 2004; 58:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dy GK, Prasad D, Kumar P, et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy. J Thorac Oncol 2021; 16:e19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rimner A, Moore ZR, Lobaugh S, et al. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. Int J Radiat Oncol Biol Phys 2023; 116:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theuws JC, Seppenwoolde Y, Kwa SL, et al. Changes in local pulmonary injury up to 48 months after irradiation for lymphoma and breast cancer. Int J Radiat Oncol Biol Phys 2000; 47:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005; 63:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonadou D, Petridis A, Synodinou M, et al. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 2003; 30:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giridhar P, Mallick S, Rath GK, Julka PK. Radiation induced lung injury: prediction, assessment and management. Asian Pac J Cancer Prev 2015; 16:2613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001; 51:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward WF, Molteni A, Ts'ao CH. Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817. Radiat Res 1989; 117:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012; 84:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao Z, Liang R, Wang CQ, et al. Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer?: A meta-analysis of 16 randomized controlled trials following the PRISMA guidelines. Medicine (Baltimore) 2016; 95:e4517.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4331 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Rapport sur l'action des rayons X sur la tuberculose
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Intrathoracic changes induced by heavy irradiation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11804681" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lung toxicity following chest irradiation in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3549278" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Radiation effects in the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7713782" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8362081" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Radiopathology of the lung: experimental and clinical observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9106589" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pulmonary radiation injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936538" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Challenges in defining radiation pneumonitis in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487552" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035956" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28477633" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Radiation Pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755559" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11020572" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385415" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The clinical characteristics and non-steroidal treatment for radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25924810" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25863764" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9719112" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171801" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11917281" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Radiation pneumonitis and early circulatory cytokine markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11172944" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Circulating IL-6 as a predictor of radiation pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7642437" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18006824" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Distinct loci influence radiation-induced alveolitis from fibrosing alveolitis in the mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22144075" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Predicting toxicity from radiation therapy--it's genetic, right?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24780874" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18027873" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Genetic predictors of long-term toxicities after radiation therapy for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17889263" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325707" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22144047" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171797" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : ATM polymorphisms are associated with risk of radiation-induced pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23154078" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829134" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17905467" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9837692" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8256918" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Radiation pneumonitis. Bronchoalveolar lavage assessment and modulation by a recombinant cytokine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33610273" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Biology of Radiation-Induced Lung Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17921108" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17926943" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A neural network model to predict lung radiation-induced pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19380441" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171521" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Radiation dose-volume effects in the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171502" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of normal tissue complication probability models in the clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11777631" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2061112" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8174052" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15703313" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150598" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Total body irradiation and pneumonitis risk: a review of outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9747813" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15817337" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29976504" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical and Dosimetric Factors Predicting Grade≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7595714" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20085905" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17689035" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28034064" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23374503" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27421817" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28244414" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28011047" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27325482" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25276313" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Radiation pneumonitis after stereotactic radiation therapy for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30496880" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26995159" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21437893" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27090216" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29293386" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36104272" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11734597" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18317071" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17276621" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12865175" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19550240" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : "The best-laid plans ... often go awry ...".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22331948" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19018081" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22425919" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22950387" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10550832" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The role of radiation, with or without chemotherapy, in the management of NSCLC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487963" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18556142" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19096311" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18487565" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22377772" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Interstitial pneumonitis after treatment with pemetrexed: a rare event?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11955753" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751058" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26811519" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30267842" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885881" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32372571" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31982496" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34989781" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35947522" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35094066" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33622352" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27036494" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25376512" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28581404" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27068780" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29066051" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072613" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32105810" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A Primer on Interstitial Lung Disease and Thoracic Radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8475291" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : "Recall" pneumonitis: adriamycin potentiation of radiation pneumonitis in two children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8625210" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17406804" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Radiation recall pneumonitis induced by gemcitabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12023144" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Gemcitabine-induced radiation recall.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1324465" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : [A case with delayed-onset radiation pneumonitis suspected to be induced by oral etoposide].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27420135" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Pulmonary Radiation Recall Induced by Gemcitabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846159" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31031204" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31176579" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220368" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10924976" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9486572" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23726005" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9886696" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21885726" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22230037" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Challenges scoring radiation pneumonitis in patients irradiated for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/257714" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : [Management of alcoholics by the general practitioner].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21640513" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24661663" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28584268" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32754317" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Risk of radiation pneumonitis in patients with emphysema after stereotactic body radiotherapy for non-small cell lung cancer assessed by quantitative CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21549513" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21549513" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10362031" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/319723" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Pulmonary effects of radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15062608" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Pulmonary complications of radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12649121" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12423687" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577017" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24195693" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9987529" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Radiation-induced pneumonitis in the "nonirradiated" lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9707467" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Corticosteroids and azathioprine do not prevent radiation-induced lung injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20584582" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10682774" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Radiation-induced lung disease and the impact of radiation methods on imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15256622" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936539" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26334751" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline Nor Post-SBRT Pulmonary Function Are Associated with Worse Overall Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22768989" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12115368" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7836090" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8567349" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32076108" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The role of procalcitonin in differential diagnosis between acute radiation pneumonitis and bacterial pneumonia in lung cancer patients receiving thoracic radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803021" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Suggestion for a new grading scale for radiation induced pneumonitis based on radiological findings of computerized tomography: correlation with clinical and radiotherapeutic parameters in lung cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803021" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Suggestion for a new grading scale for radiation induced pneumonitis based on radiological findings of computerized tomography: correlation with clinical and radiotherapeutic parameters in lung cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803021" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Suggestion for a new grading scale for radiation induced pneumonitis based on radiological findings of computerized tomography: correlation with clinical and radiotherapeutic parameters in lung cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26830686" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21193785" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3340715" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Protective effect of corticosteroids on radiation pneumonitis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14697441" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33641724" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36889516" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10889373" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Changes in local pulmonary injury up to 48 months after irradiation for lymphoma and breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15963660" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14727235" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25854336" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Radiation induced lung injury: prediction, assessment and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11704311" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2922477" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22300564" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27583861" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer?: A meta-analysis of 16 randomized controlled trials following the PRISMA guidelines.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
